Press

[section title=”Business News ” id=”section4″ wide=true typography_md=”H2 {line-height: 28.57142858px;font-size: 20px;}” css_sm=”padding-top:4em;padding-bottom:4em;” css_xs=”padding-top:4em;padding-bottom:4em;” css=”padding-top:2em;padding-bottom:0em;background-size:contain;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #333333;}TextLinkPassive {color: #5cb75c;}H2 {line-height: 20px;font-size: 20px;font-weight: bold;text-transform: none;letter-spacing: 1px;color: #0070c0;}H1 {line-height: 36px;font-size: 36px;text-transform: none;color: #000000;font-weight: 600;letter-spacing: 1px;}”]
[columns auto_height=1 vertical_align=”top” add_margins=true spacing_css_xs=”margin-top:-15px;margin-bottom:-15px;padding-top:15px;padding-bottom:15px;height:calc(130%);” spacing_css=”margin-left:-15px;margin-right:-15px;padding-left:15px;padding-right:15px;”]
[column width_xs=”12″ css=”padding-bottom:1em;” typography=”Text {text-align: center;}”]
[text tag=”h1″ typography_xs=”Text {line-height: 42.85714287px;font-size: 30px;}” css=”margin-bottom:0px;” typography=”Text {line-height: 68.57142859px;font-size: 48px;color: #0070c0;}”]Press Releases[/text]

[spacer css=”height:20px;”][/spacer]

[separator content_type=”none” text=”Caption” text_tag=”span” align=”center” content_align=”center” href=”#” image=”https://cstatic.themler.io/themler/483/images/defaultImage.jpg” css=”margin-top:0px;margin-bottom:0px;padding:10px 0px;” image_css=”display:inline-block;” content_typography=”Text {color: #777777;}” line_css=”width:10%;border-top:2px solid #000000;”][/separator]
[/column]
[/columns]
[/section]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#ffffff;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #002061;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]September 24, 2019[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;font-size: 18px;color: #777777;}”]Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing. The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and insiders MPM Capital, funds managed by Tekla Capital Management LLC and Franklin Berger…[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/07/3682483_bd_media_id_5d269de74f9542b112f6600ddcc932e3.jpeg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#f5f5f5;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #002061;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena’s Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at the European Hematology Association Annual Meeting[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]July 1, 2019[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;font-size: 18px;color: #777777;}”]Amphivena Therapeutics highlighted initial data from the doseescalation portion of the First-in-Human Phase 1 trial evaluating AMV564 in patients with relapsed or refractory acute myeloid leukemia (AML, AMV564-101, NCT03144245) in an oral presentation June 15 at the 24th European Hematology Association (EHA) meeting in Amsterdam (Abstract S877). The oral presentation of data from 33 patients treated within 9 cohorts demonstrated that AMV564 is active in relapsed or refractory AML and expanded upon the data from 26 patients presented at the Annual Meeting of the American Society of Hematology in December 2018…[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/07/2485055_bd_media_id_985ba4e960d12e835fe001b1823d4f17.jpeg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#ffffff;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #002061;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena Expands Executive Team[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]March 5, 2019[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;font-size: 18px;color: #777777;}”]Amphivena Therapeutics, Inc., a privately held clinical stage immuno-oncology (I/O) company that develops T cell engager therapeutics for myeloid malignancies and solid tumors, announced today the appointment of Victoria Smith, Ph.D. to the position of Chief Scientific Officer. Separately, the company said that Peter Van Vlasselaer, Ph.D. joined the Amphivena Board of Directors as an independent Executive Chairman…[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/07/3682483_bd_media_id_5d269de74f9542b112f6600ddcc932e3.jpeg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#f5f5f5;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #002061;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena Presents at ASH First-in -Human Phase 1 Clinical Data on AMV564[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]December 3, 2018[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;font-size: 18px;color: #777777;}”]Amphivena Therapeutics, Inc., a privately held biotechnology company developing AMV564, a CD33/CD3 T cell engager for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), presented Saturday night in a poster presentation at the 60th Annual Meeting of the American Society of Hematology first-in-human Phase 1 clinical data that demonstrate that in patients with relapsed/refractory AML, AMV564 is well-tolerated and has anti-leukemic activity through T-cell engagement…[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/07/2485055_bd_media_id_985ba4e960d12e835fe001b1823d4f17.jpeg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#ffffff;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #002061;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena Presents Preclinical Data at ASH that Points to a Potentially New Treatment for MDS Patients[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]December 9, 2017[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;font-size: 18px;color: #777777;}”]AmphivenaTherapeutics Inc., a privately held biotechnology company developing AMV564, a CD33/CD3 T cell redirector for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), will present today in an oral presentation at the 59thAnnual Meeting of the American Society of Hematology preclinical data that demonstrate that treatment with AMV564 selectively depletes myeloid-derived suppressor cells (MDSCs) in bone marrow cells from patients with MDS with resultant reactivation of T lymphocytes…[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/07/3682483_bd_media_id_5d269de74f9542b112f6600ddcc932e3.jpeg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#f5f5f5;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #002061;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena Receives Orphan Drug Designation for AMV564, a Novel CD33/CD3 T-Cell Engagement Therapy for the Treatment of Acute Myeloid Leukemia[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]March 5, 2019[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;font-size: 18px;color: #777777;}”]Amphivena Therapeutics Inc., a privately held biotechnology company developing a novel CD33/CD3 T cell engager for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), announced today that it has received Orphan Drug Designation from the U.S. Food and Drug Administration for its lead compound AMV564 for the treatment of AML[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/07/2485055_bd_media_id_985ba4e960d12e835fe001b1823d4f17.jpeg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#ffffff;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #002061;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena Announces New Key Leadership and Advisors – Tekla Invests in Series B Round[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]September 11, 2017[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;font-size: 18px;color: #777777;}”]Amphivena Therapeutics, Inc., a privately held biotechnology company developing a novel CD33/CD3-bispecific T cell engaging antibody for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), is pleased to announce three additions to the company’s leadership team…[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/07/3682483_bd_media_id_5d269de74f9542b112f6600ddcc932e3.jpeg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#f5f5f5;” typography=”Text {line-height: 27.2px;color: #002061;font-size: 16px;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena Therapeutics Announces Acceptance of Investigational New Drug (IND) Application for AMV564 and Planned Phase 1 Trial Initiation[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]August 10, 2016[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;color: #777777;font-size: 18px;}”]Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for AMV564, the company’s proprietary T-cell redirecting bispecific CD33/CD3 antibody. The company plans to initiate a Phase 1 dose escalation and expansion trial of AMV564 in acute myeloid leukemia (AML) patients this year…[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/07/2485055_bd_media_id_985ba4e960d12e835fe001b1823d4f17.jpeg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#ffffff;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #002061;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena Therapeutics to Present Data on Novel Cancer Immunotherapy at 2015 ASCO Annual Meeting[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]May 26, 2015[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;font-size: 18px;color: #777777;}”]Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, today announced that the company will present data from its novel cancer immunotherapy program in acute myeloid leukemia (AML) for the first time in three poster presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2015 in Chicago. In multiple studies, Amphivena’s proprietary T-cell redirecting bispecific antibodies demonstrated potent and selective killing of CD33+ AML cells in vitro and impressive activity in AML animal models in vivo…[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/07/3682483_bd_media_id_5d269de74f9542b112f6600ddcc932e3.jpeg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]

[fluid][section title=”One Third” id=”section4″ wide=true css=”background-color:#f5f5f5;” typography=”Text {line-height: 27.2px;font-size: 16px;color: #002061;}H1 {line-height: 16.8px;font-size: 14px;font-weight: 400;color: #002061;}”]
[fluid_1][columns auto_height=1 vertical_align=”middle” add_margins=false spacing_css=”margin-left:0px;margin-right:0px;padding-left:0px;padding-right:0px;”]
[column width_sm=”8″ css=”padding:1em 7%;”]
[text tag=”h1″ css=”margin-top:11px;” typography=”Text {line-height: 34.2857143px;font-size: 24px;}”]Amphivena Therapeutics Achieves Development Milestones Under Agreement With Janssen[/text]

[text tag=”p” typography=”Text {line-height: 20.00000001px;font-size: 14px;}”]April 7, 2015[/text]

[spacer css=”height:1em;”][/spacer]

[text tag=”p” typography=”Text {line-height: 30.6px;font-size: 18px;color: #777777;}”]Amphivena Therapeutics, Inc., a developer of cancer immunotherapeutics, today announced the achievement of the first and second milestones under the terms of its agreement with Janssen Biotech, Inc. Amphivena and Janssen have selected a clinical candidate against an undisclosed tumor antigen for further development in hematologic malignancies. The milestones triggered the release of payments to Amphivena. The financial details were not disclosed. The agreement was facilitated by Johnson & Johnson Innovation…[/text]

[spacer css_md=”height:1em;” css=”height:1.25em;margin-bottom:-16px;”][/spacer]


[/column]

[column width_sm=”4″ css_xs=”min-height:70vw;” css=”background-image:url(https://amphivena.com/wp-content/uploads/2019/05/amphivena-development-researches.jpg);background-repeat:repeat;background-attachment:scroll;background-position:center center;background-size:cover;min-height:30vw;”]

[/column]
[/columns][/fluid_1]
[/section][/fluid]